(NASDAQ: BCYC) Bicycle Therapeutics's forecast annual revenue growth rate of 80.18% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 113.44%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.93%.
Bicycle Therapeutics's revenue in 2026 is $28,339,000.On average, 16 Wall Street analysts forecast BCYC's revenue for 2026 to be $2,204,719,839, with the lowest BCYC revenue forecast at $212,751,337, and the highest BCYC revenue forecast at $4,370,177,448. On average, 15 Wall Street analysts forecast BCYC's revenue for 2027 to be $3,507,934,501, with the lowest BCYC revenue forecast at $197,143,560, and the highest BCYC revenue forecast at $9,127,427,756.
In 2028, BCYC is forecast to generate $13,193,080,140 in revenue, with the lowest revenue forecast at $2,719,221,523 and the highest revenue forecast at $28,709,291,118.